SOD1 and type 2 diabetes mellitus: Also, in the same study, through in vivo tests with gliclazide administration for 10 months by 44 patients with T2DM, it was demonstrated that at a concentration of 1 μM gliclazide, there was a significant inhibition of 8-isoprostanes, specific markers of lipid oxidation, and an increase in SOD, TPAC parameters, thus having notable antioxidant properties with clinical effects [113].